Calcium entry blocking activities of MPC-1304 and of its enantiomers and metabolites

Abstract

The Ca 2+ entry blocking effects of MPC-1304, a new Ca 2+ entry blocker of the 1,4-dihydropyridine type, and of its (S) and (R) enantiomers and metabolites were examined on Ca 2+-induced contractions in isolated rabbit arteries. The Ca 2+ entry blocking activity of the (S) enantiomer of MPC-1304 was approximately 150 times greater that that of its (R) enantiomer. Likewise, the antihypertensive effect of the (S) enantiomer was twice as great as that of MPC-1304 (racemate) in conscious spontaneously hypertensive rats, while the (R) enantiomer was ineffective. Thus, most of the pharmacological activity of MPC-1304 resides in its (S) configuration. The main metabolic products of MPC-1304 lso inhibited the Ca 2+-induced contraction in the isolated vascular smooth muscles. These active metabolites showed a stereoselectivity similar to that of MPC-1304 for Ca 2+ entry blocking activity, and may contribute to the potent antihypertensive action of MPC-1304.